Caseware UK (AP4) 2023.0.135 2023.0.135 2023-07-312023-07-31The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false2022-08-01Medical services11falsetrue 10278478 2022-08-01 2023-07-31 10278478 2021-08-01 2022-07-31 10278478 2023-07-31 10278478 2022-07-31 10278478 c:Director1 2022-08-01 2023-07-31 10278478 d:MotorVehicles 2022-08-01 2023-07-31 10278478 d:MotorVehicles 2023-07-31 10278478 d:MotorVehicles 2022-07-31 10278478 d:MotorVehicles d:OwnedOrFreeholdAssets 2022-08-01 2023-07-31 10278478 d:FurnitureFittings 2022-08-01 2023-07-31 10278478 d:FurnitureFittings 2023-07-31 10278478 d:FurnitureFittings 2022-07-31 10278478 d:FurnitureFittings d:OwnedOrFreeholdAssets 2022-08-01 2023-07-31 10278478 d:OwnedOrFreeholdAssets 2022-08-01 2023-07-31 10278478 d:CurrentFinancialInstruments 2023-07-31 10278478 d:CurrentFinancialInstruments 2022-07-31 10278478 d:Non-currentFinancialInstruments 2023-07-31 10278478 d:Non-currentFinancialInstruments 2022-07-31 10278478 d:CurrentFinancialInstruments d:WithinOneYear 2023-07-31 10278478 d:CurrentFinancialInstruments d:WithinOneYear 2022-07-31 10278478 d:Non-currentFinancialInstruments d:AfterOneYear 2023-07-31 10278478 d:Non-currentFinancialInstruments d:AfterOneYear 2022-07-31 10278478 d:ShareCapital 2023-07-31 10278478 d:ShareCapital 2022-07-31 10278478 d:RetainedEarningsAccumulatedLosses 2023-07-31 10278478 d:RetainedEarningsAccumulatedLosses 2022-07-31 10278478 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2023-07-31 10278478 d:FinancialAssetsDesignatedFairValueThroughProfitOrLoss 2022-07-31 10278478 c:FRS102 2022-08-01 2023-07-31 10278478 c:AuditExempt-NoAccountantsReport 2022-08-01 2023-07-31 10278478 c:FullAccounts 2022-08-01 2023-07-31 10278478 c:PrivateLimitedCompanyLtd 2022-08-01 2023-07-31 10278478 d:HirePurchaseContracts d:WithinOneYear 2023-07-31 10278478 d:HirePurchaseContracts d:WithinOneYear 2022-07-31 10278478 d:HirePurchaseContracts d:BetweenOneFiveYears 2023-07-31 10278478 d:HirePurchaseContracts d:BetweenOneFiveYears 2022-07-31 10278478 2 2022-08-01 2023-07-31 10278478 6 2022-08-01 2023-07-31 iso4217:GBP xbrli:pure

Registered number: 10278478









SARUM EYE CLINIC LIMITED







UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JULY 2023

 
SARUM EYE CLINIC LIMITED
REGISTERED NUMBER: 10278478

BALANCE SHEET
AS AT 31 JULY 2023

2023
2022
Note
£
£

Fixed assets
  

Tangible assets
 4 
72,209
66,441

Investments
 5 
50
50

  
72,259
66,491

Current assets
  

Debtors: amounts falling due within one year
 6 
40,446
61,162

Cash at bank and in hand
 7 
314,771
344,148

  
355,217
405,310

Creditors: amounts falling due within one year
 8 
(52,110)
(131,587)

Net current assets
  
 
 
303,107
 
 
273,723

Total assets less current liabilities
  
375,366
340,214

Creditors: amounts falling due after more than one year
 9 
(39,820)
(51,870)

  

Net assets
  
335,546
288,344


Capital and reserves
  

Called up share capital 
  
200
200

Profit and loss account
  
335,346
288,144

  
335,546
288,344


Page 1

 
SARUM EYE CLINIC LIMITED
REGISTERED NUMBER: 10278478
    
BALANCE SHEET (CONTINUED)
AS AT 31 JULY 2023

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 30 July 2024.




................................................
Naeem Haq
Director

The notes on pages 3 to 7 form part of these financial statements.

Page 2

 
SARUM EYE CLINIC LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

1.


General information

Sarum Eye Clinic Limited is a private company, incorporated in England and Wales, limited by its share capital.  The principal activity of the Company was the provision of medical services.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.5

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Page 3

 
SARUM EYE CLINIC LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

2.Accounting policies (continued)

 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Motor vehicles
-
20%
reducing balance
Fixtures and fittings
-
25%
reducing balance

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of income and retained earnings for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.

 
2.8

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.9

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.10

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 4

 
SARUM EYE CLINIC LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

2.Accounting policies (continued)

 
2.11

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

 
2.12

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 1 (2022 - 1).


4.


Tangible fixed assets





Motor vehicles
Fixtures and fittings
Total

£
£
£



Cost or valuation


At 1 August 2022
103,066
850
103,916


Additions
23,850
-
23,850



At 31 July 2023

126,916
850
127,766



Depreciation


At 1 August 2022
37,104
371
37,475


Charge for the year on owned assets
17,962
120
18,082



At 31 July 2023

55,066
491
55,557



Net book value



At 31 July 2023
71,850
359
72,209



At 31 July 2022
65,962
479
66,441

Page 5

 
SARUM EYE CLINIC LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

5.


Fixed asset investments





Unlisted investments

£



Cost or valuation


At 1 August 2022
50



At 31 July 2023
50





6.


Debtors

2023
2022
£
£


Trade debtors
10,056
30,772

Amounts owed by group undertakings
30,390
30,390

40,446
61,162



7.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
314,771
344,148

314,771
344,148



8.


Creditors: Amounts falling due within one year

2023
2022
£
£

Amounts owed to group undertakings
2,486
-

Corporation tax
31,058
33,950

Obligations under finance lease and hire purchase contracts
16,790
16,790

Other creditors
-
79,071

Accruals and deferred income
1,776
1,776

52,110
131,587


Page 6

 
SARUM EYE CLINIC LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023

9.


Creditors: Amounts falling due after more than one year

2023
2022
£
£

Net obligations under finance leases and hire purchase contracts
39,820
51,870

39,820
51,870



10.


Hire purchase and finance leases


Minimum lease payments under hire purchase fall due as follows:

2023
2022
£
£


Within one year
16,789
16,789

Between 1-5 years
39,820
51,870

56,609
68,659


11.


Financial instruments

2023
2022
£
£

Financial assets


Financial assets measured at fair value through profit or loss
314,771
344,148




Financial assets measured at fair value through profit or loss comprise cash at bank and in hand.


12.


Controlling party

There is no overall controlling party.

 
Page 7